Find an abstract and a link to most of the publications produced by Nordic Bioscience
KBP-042 is a dual amylin and calcitonin receptor agonist that increases glucose tolerance and insulin action and reduces body weight in rat models of obesity and prediabetes. The objective of the present study was to 1) evaluate KBP-042 as a treatment of late-stage type 2 diabetes in a rat model and...
April 24, 2017
Journal:
J Pharmacol Exp Ther
Author:
Hjuler ST, Gydesen S, Andreassen KV, Karsdal MA, Henriksen K
Amylin and GLP-1 agonism induce a well-known anorexic effect at dose initiation, which is managed by dose escalation. In this study we investigated how to optimize tolerability while maintaining efficacy of a novel, highly potent dual amylin and calcitonin receptor agonist (DACRA), KBP-089. Furtherm...
March 14, 2017
Journal:
Am J Physiol Endocrinol Metab
Author:
Gydesen S, Andreassen KV, Hjuler ST, Hellgren LI, Karsdal MA, Henriksen K
Amylin and GLP-1 agonism induce a well-known anorexic effect at dose initiation, which is managed by dose escalation. In this study we investigated how to optimize tolerability while maintaining efficacy of a novel, highly potent dual amylin and calcitonin receptor agonist (DACRA), KBP-089. Furtherm...
January 21, 2017
Journal:
Br J Clin Pharmacol
Author:
Gydesen S, Hjuler ST, Freving Z, Andreassen KV, Sonne N, Hellgren LI, Karsdal MA, Henriksen K
OBJECTIVE: In this study, KBP-042, a dual amylin- and calcitonin-receptor agonist, was investigated as a treatment of obesity and insulin resistance in five different doses (0.625 µg/kg-10 µg/kg) compared with saline-treated and pair-fed controls. METHODS: Rats with obesity received daily s.c. admi...
August 1, 2016
Journal:
Br J Clin Pharmacol
Author:
Hjuler ST, Gydesen S, Andreassen KV, Pedersen SL, Hellgren LI, Karsdal MA, Henriksen K
This study aims to elucidate the mechanism behind the potent weight loss induced by dual amylin and calcitonin receptor agonists (DACRA) through comparison of the novel DACRA KBP-088 with the amylinomimetic davalintide with regard to in vitro receptor pharmacology and in vivo efficacy on food intake...
May 1, 2016
Journal:
Am J Physiol Endocrinol Metab
Author:
Gydesen S, Hjuler ST, Christensen JM, Karsdal MA, Arbit E, Andreassen KV
KBP-042 is a synthetic peptide dual amylin- and calcitonin-receptor agonist (DACRA) developed to treat type 2 diabetes by inducing a significant weight loss while improving glucose homeostasis. In this study the aim was to compare two different formulations: An oral formulation (1mg/kg) to subcutane...
September 5, 2015
Journal:
Eur J Pharmacol
Author:
Hjuler ST, Andreassen KV, Gydesen S, Karsdal MA, Henriksen K
We previously reported that oral delivery of salmon calcitonin (sCT) improved energy and glucose homeostasis and attenuated diabetic progression in animal models of diet-induced obesity (DIO) and type 2 diabetes, although the glucoregulatory mode of action was not fully elucidated. In the present st...
May 22, 2014
Journal:
Eur J Pharmacol
Author:
Feigh M, Andreassen KV, Gydesen S, Ottosen I, Henriksen JE, Beck-Nielsen H, Christiansen H, Karsdal MA, Henriksen K
The present study investigated a novel oral dual amylin and calcitonin receptor agonist (DACRA), KBP-042, in head-to-head comparison with salmon calcitonin (sCT) with regard to in vitro receptor pharmacology, ex vivo pancreatic islet studies, and in vivo proof of concept studies in diet-induced obes...
May 6, 2014
Journal:
Am J Physiol Endocrinol Metab
Author:
Andreassen KV, Feigh M, Hjuler ST, Gydesen S, Henriksen JE, Beck-Nielsen H, Christiansen C, Karsdal MA, Henriksen K
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.